Introduction
Moderna had a very good three months. The company made much more money than experts thought it would. Its shares went up before the stock market opened on Friday. Moderna makes vaccines. A vaccine is a shot that helps your body fight a sickness.
What Happened
Moderna shared its results for the third quarter of 2026 on Friday, November 6. The company made $1.31 billion in sales in those three months. That is 29% more than the same three months last year. Experts had thought the company would make only $885.1 million.
Moderna also made a profit. A profit means the company kept money after paying its costs. Its profit was $162 million, or 38 cents for each share. A share is a small piece of a company. Experts had thought Moderna would lose $1.25 for each share, so this was a big surprise. A year ago, Moderna lost $200 million in the same three months.
Key Figures
- Sales: $1.31 billion, up 29% from last year
- Profit: $162 million, or 38 cents per share
- Experts expected: $885.1 million in sales and a loss of $1.25 per share
- Sales in the United States: $780 million; sales in other countries: $533 million
- Shares: up about 5% before the market opened on Friday
- Money in the bank: $8.0 billion at the end of September
Why It Happened
More people bought Moderna’s shots than experts had thought. Demand for its Covid shots was strong in other countries. Moderna also has new shots that are selling well. Its new flu shot, called mFLUSIVA, was approved in the United States in August.
The company’s boss, Stephane Bancel, said the new products are doing well. He said, “Our newer products are delivering. They are selling well, and there is momentum across the business.” Momentum means things keep moving in a good direction. Good news about a cancer vaccine also helped the company. In October, a big test of the cancer vaccine gave good results for people with a type of skin cancer called melanoma.
Why It Matters
This news matters because Moderna had a hard time after Covid. Sales of Covid shots fell a lot when the pandemic ended. Now the company is growing again. It is also working on a cancer vaccine with the drug company Merck. That vaccine is made for each person, so it fits that person’s cancer.
Moderna’s shares have gone up more than 700% this year. Much of that jump came from hope about the cancer vaccine. This good news came in a hard week for the wider market, too. The Nasdaq fell 5.52% and entered a correction this week.
What Happens Next
Moderna now thinks its sales will grow faster in 2026. It expects sales to grow by 15% to 25% for the full year. Before, it had said sales would grow by up to 10%. That is a much better outlook.
Moderna will hold a big meeting for investors on November 12. Investors are people who own shares in a company. The company will share more plans at that meeting. Apple and Palantir also reported their results at the start of a huge week for stocks.
Final Thoughts
Moderna beat the experts by a lot. Its sales were much higher than expected, and it made a profit instead of a loss. The new flu shot and the cancer vaccine give the company more ways to grow. For now, this was a strong result for Moderna.
Quick Questions
How much money did Moderna make in the third quarter of 2026?
Moderna made $1.31 billion in sales. That was 29% more than the same three months last year.
Did Moderna make a profit or a loss?
Moderna made a profit of $162 million. That is 38 cents for each share.
Why did Moderna raise its outlook for 2026?
Its new shots are selling well. So it now expects sales to grow by 15% to 25% in 2026, up from up to 10% before.
Disclaimer: This article is for educational and informational purposes only and does not constitute financial advice.
Sources: CNBC: Moderna (MRNA) earnings Q3 2026 and Moderna: Third Quarter 2026 Financial Results and Business Updates.
Leave a Reply